How Somite Therapeutics and OmniaBio Are Revolutionizing Cell Therapy for Duchenne Muscular Dystrophy
In an exciting new collaboration, Somite Therapeutics and OmniaBio Inc. have joined forces to advance Somite’s flagship cell therapy program, targeting the devastating genetic disorder Duchenne Muscular Dystrophy (DMD). This strategic partnership leverages Somite’s cutting-edge use of AI-driven cell replacement therapies and OmniaBio’s expertise in induced pluripotent stem cells (iPSCs) to bring hope to individuals […]